This could explain why tirzepatide (which stimulates the GIP pathway in addition to GLP -1) can be administered at higher doses than semaglutide (which only stimulates GLP-1), without amplifying the side effects typical of GLP-1 agonists (nausea, vomiting)
When GLP-1 treatments hit the market in the early 2000s, Breakthrough T1D and others funded several clinical trials to test whether GLP-1 receptor agonists, in addition to insulin, improved outcomes for people with type 1 diabetes
Double the units means double the precision, because each unit represents half the dose
Scientists have developed a new laboratory method to detect the use of performance-enhancing drugs like CJC-1295
I was skeptical at first because of my past experiences, but my entire weight loss journey with SheMed has been great
The Connectivity Map has limitations